Literature DB >> 9184148

The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.

B Turk1, I Brieditis, S C Bock, S T Olson, I Björk.   

Abstract

The beta-form of antithrombin, lacking a carbohydrate side chain on Asn-135, is known to bind heparin more tightly than the fully glycosylated alpha-form. The molecular basis for this difference in affinity was elucidated by rapid-kinetic studies of the binding of heparin and the antithrombin-binding heparin pentasaccharide to plasma and recombinant forms of alpha- and beta-antithrombin. The dissociation equilibrium constant for the first step of the two-step mechanism of binding of both heparin and pentasaccharide to alpha-antithrombin was only slightly higher than that for the binding to the beta-form. The oligosaccharide at Asn-135 thus at most moderately interferes with the initial, weak binding of heparin to alpha-antithrombin. In contrast, the rate constant for the conformational change induced by heparin and pentasaccharide in the second binding step was substantially lower for alpha-antithrombin than for beta-antithrombin. Moreover, the rate constant for the reversal of this conformational change was appreciably higher for the alpha-form than for the beta-form. The carbohydrate side chain at Asn-135 thus reduces the heparin affinity of alpha-antithrombin primarily by interfering with the heparin-induced conformational change. These and previous results suggest a model in which the Asn-135 oligosaccharide of alpha-antithrombin is oriented away from the heparin binding site and does not interfere with the first step of heparin binding. This initial binding induces conformational changes involving extension of helix D into the adjacent region containing Asn-135, which are transmitted to the reactive-bond loop. The resulting decreased conformational flexibility of the Asn-135 oligosaccharide and its close vicinity to the heparin binding site destabilize the activated relative to the native conformation. This effect results in a higher energy for inducing the activated conformation in alpha-antithrombin, leading to a decrease in heparin binding affinity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184148     DOI: 10.1021/bi9702492

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  18 in total

1.  Characterization of the conformational alterations, reduced anticoagulant activity, and enhanced antiangiogenic activity of prelatent antithrombin.

Authors:  Benjamin Richard; Richard Swanson; Sophia Schedin-Weiss; Ben Ramirez; Gonzalo Izaguirre; Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2008-03-28       Impact factor: 5.157

2.  Kinetic evidence that allosteric activation of antithrombin by heparin is mediated by two sequential conformational changes.

Authors:  Sophia Schedin-Weiss; Benjamin Richard; Steven T Olson
Journal:  Arch Biochem Biophys       Date:  2010-09-15       Impact factor: 4.013

3.  Conformational activation of antithrombin by heparin involves an altered exosite interaction with protease.

Authors:  Gonzalo Izaguirre; Sonia Aguila; Lixin Qi; Richard Swanson; Ryan Roth; Alireza R Rezaie; Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

4.  Saturation Mutagenesis of the Antithrombin Reactive Center Loop P14 Residue Supports a Three-step Mechanism of Heparin Allosteric Activation Involving Intermediate and Fully Activated States.

Authors:  Ryan Roth; Richard Swanson; Gonzalo Izaguirre; Susan C Bock; Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2015-09-10       Impact factor: 5.157

5.  The heparin-binding site of antithrombin is crucial for antiangiogenic activity.

Authors:  Weiqing Zhang; Richard Swanson; Gonzalo Izaguirre; Yan Xiong; Lester F Lau; Steven T Olson
Journal:  Blood       Date:  2005-05-19       Impact factor: 22.113

6.  The signature 3-O-sulfo group of the anticoagulant heparin sequence is critical for heparin binding to antithrombin but is not required for allosteric activation.

Authors:  Benjamin Richard; Richard Swanson; Steven T Olson
Journal:  J Biol Chem       Date:  2009-08-06       Impact factor: 5.157

7.  Protective effect of a newly developed fucose-deficient recombinant antithrombin against histone-induced endothelial damage.

Authors:  Toshiaki Iba; Tatsuhiko Hirota; Koichi Sato; Isao Nagaoka
Journal:  Int J Hematol       Date:  2018-01-20       Impact factor: 2.490

Review 8.  Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

Authors:  Daniel K Afosah; Rami A Al-Horani
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

9.  Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II.

Authors:  Suryakala Sarilla; Sally Y Habib; Dmitri V Kravtsov; Anton Matafonov; David Gailani; Ingrid M Verhamme
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

Review 10.  Heparin-binding domains in vascular biology.

Authors:  Eva M Muñoz; Robert J Linhardt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-07-01       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.